Fenske W, Sandner B, Christ-Crain M
Leipzig University Medical Center, Integrated Research and Treatment Center for Adiposity Diseases, Leipzig, Germany.
Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.
Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):219-33. doi: 10.1016/j.beem.2016.02.013. Epub 2016 Mar 2.
The syndrome of inappropriate antidiuretic hormone secretion (SIADH), also referred to as syndrome of inappropriate antidiuresis (SIAD), is the most common cause of hyponatremia characterized by extracellular hypotonicity and impaired urine dilution in the absence of any recognizable nonosmotic stimuli for the antidiuretic hormone arginine vasopressin (AVP). Hyponatremia in SIADH is primarily the result of excessive water retention caused by a combination of inappropriate antidiuresis and persistent fluid intake in the presence of impaired osmoregulated inhibition of thirst. It is sometimes aggravated by a sodium deficiency caused by a decreased intake or a secondary natriuresis in response to elevated extracellular volume. Inappropriate antidiuresis usually results from endogenous production of AVP that can be either ectopic (from a malignancy) or eutopic (from the hypothalamus/neurohypophysis). Regardless of its origin, different types of osmotic dysregulation of AVP have been reported with possibly fundamental deviations in treatment need and efficacy. A recent quantitative analysis of 50 patients with SIADH, which underwent serial measurements of copeptin during hypertonic saline infusion, revealed five distinct types of osmoregulatory defect ("type A to E") without affiliation to specific underlying diseases. In addition to apparently impaired osmoregulated inhibition of AVP release in the majority of patients, 12% of patients showed an AVP-independent mechanism of inappropriate antidiuresis, whilst 20% of them presented a reverse relation between hormone release and serum osmolality, presumably related to interrupted nonosmotic inhibitory pathways. The interference of these different types of SIAD with clinical presentation and therapy response will be a relevant subject for future research.
抗利尿激素分泌不当综合征(SIADH),也称为抗利尿不当综合征(SIAD),是低钠血症最常见的病因,其特征为细胞外低渗状态以及在缺乏任何可识别的抗利尿激素精氨酸加压素(AVP)非渗透性刺激的情况下尿液稀释功能受损。SIADH中的低钠血症主要是由于抗利尿不当和口渴的渗透压调节抑制受损时持续摄入液体共同导致的水潴留过多所致。有时因摄入减少或细胞外液量增加引起继发性利钠导致的钠缺乏会使病情加重。抗利尿不当通常源于AVP的内源性产生,其可能是异位性的(源于恶性肿瘤)或正常位的(源于下丘脑/神经垂体)。无论其来源如何,已有报道称AVP存在不同类型的渗透调节失调,在治疗需求和疗效方面可能存在根本性差异。最近对50例SIADH患者进行的一项定量分析显示,在高渗盐水输注期间对 copeptin 进行连续测量,发现了五种不同类型的渗透调节缺陷(“A至E型”),且与特定的基础疾病无关。除了大多数患者中AVP释放的渗透压调节抑制明显受损外,12%的患者表现出与AVP无关的抗利尿不当机制,而20%的患者激素释放与血清渗透压之间呈现相反关系,这可能与非渗透性抑制途径中断有关。这些不同类型的SIAD对临床表现和治疗反应的影响将是未来研究的一个相关课题。